Theravance Biopharma (NASDAQ:TBPH) Announces Earnings Results, Misses Estimates By $0.26 EPS

Theravance Biopharma (NASDAQ:TBPH) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.26), Zacks reports. The business had revenue of $18.75 million for the quarter, compared to the consensus estimate of $29.90 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%.

Theravance Biopharma Trading Up 3.9 %

Theravance Biopharma stock traded up $0.36 during trading hours on Thursday, hitting $9.44. 230,592 shares of the stock traded hands, compared to its average volume of 206,624. Theravance Biopharma has a one year low of $7.44 and a one year high of $10.90. The company has a market cap of $464.06 million, a PE ratio of -9.38 and a beta of 0.21. The firm’s 50-day moving average price is $9.35 and its two-hundred day moving average price is $8.91.

Insider Transactions at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at $2,786,085. This represents a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 6.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a report on Tuesday. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $13.75.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.